CFTR and cystic fibrosis: Treating cells with VX-445 plus VX-661, correctors in the recent combination CF drug Trikafta, increased 3HA–F508del-CFTR immunofluorescence at the cell surface (compare Fig. S5E with Fig. S5C, see also Fig. 5G).